ci 934 has been researched along with norfloxacin in 12 studies
| Studies (ci 934) | Trials (ci 934) | Recent Studies (post-2010) (ci 934) | Studies (norfloxacin) | Trials (norfloxacin) | Recent Studies (post-2010) (norfloxacin) |
|---|---|---|---|---|---|
| 33 | 0 | 2 | 3,077 | 280 | 912 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (66.67) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, MA; Domagala, JM; Mailloux, GB; Roland, GE; Suto, MJ | 1 |
| Bridges, AJ; Culbertson, TP; Domagala, JM; Gambino, L; Hagen, SE; Karrick, G; Porter, K; Sanchez, JP; Sesnie, JA; Spense, FG | 1 |
| Culbertson, TP; Gambino, L; Sanchez, JP; Sesnie, JA | 1 |
| Domagala, JM; Heifetz, CL; Hutt, MP; Mich, TF; Nichols, JB; Solomon, M; Worth, DF | 1 |
| Domagala, JM; Heifetz, CL; Mich, TF; Nichols, JB | 1 |
| García-March, FJ; Jaén-Oltra, J; Pérez-Giménez, F; Salabert-Salvador, MT; Tomás-Vert, F | 1 |
| Avesani, V; Delmee, M | 1 |
| Berlin, OG; Bruckner, DA; Young, LS | 1 |
| Habiyaremye, I; Vandepitte, J; Verbist, L | 1 |
| King, A; Phillips, I | 1 |
| Ayers, LW; Barry, AL; Fuchs, PC; Gavan, TL; Gerlach, EH; Jones, RN; Thornsberry, C | 1 |
| Floyd-Reising, SA; Hindler, JA; Kelley, SG; Young, LS | 1 |
12 other study(ies) available for ci 934 and norfloxacin
| Article | Year |
|---|---|
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
Topics: Animals; Anti-Infective Agents; Cricetinae; Cricetulus; Fluoroquinolones; Microbial Sensitivity Tests; Structure-Activity Relationship | 1992 |
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
Topics: Alkylation; Aminoquinolines; Animals; Anti-Bacterial Agents; Bacterial Infections; Chemical Phenomena; Chemistry; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Hydroxyquinolines; Mice; Microbial Sensitivity Tests; Molecular Structure; Piperazines; Pyrrolidines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1991 |
Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships.
Topics: Bacteria; Chemical Phenomena; Chemistry; Gram-Negative Bacteria; Gram-Positive Bacteria; Molecular Structure; Piperazines; Pyrrolidines; Quinolines; Spiro Compounds; Structure-Activity Relationship | 1990 |
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Carboxylic Acids; Chemical Phenomena; Chemistry; Mice; Microbial Sensitivity Tests; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1988 |
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
Topics: Animals; Anti-Bacterial Agents; Gram-Positive Bacteria; Mice; Microbial Sensitivity Tests; Naphthyridines; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1986 |
Artificial neural network applied to prediction of fluorquinolone antibacterial activity by topological methods.
Topics: Algorithms; Anti-Infective Agents; Fluoroquinolones; Microbial Sensitivity Tests; Neural Networks, Computer; Structure-Activity Relationship | 2000 |
Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
Topics: Anti-Bacterial Agents; Child; Ciprofloxacin; Clostridium; Enoxacin; Fluoroquinolones; Humans; Infant, Newborn; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines | 1986 |
In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Quinolines | 1987 |
[Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
Topics: Anti-Bacterial Agents; Campylobacter fetus; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines; Salmonella; Shigella; Vibrio cholerae; Yersinia enterocolitica | 1987 |
The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
Topics: Acinetobacter; Aeromonas; Anti-Bacterial Agents; Bacteria; Bacteria, Anaerobic; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fluoroquinolones; Gram-Positive Bacteria; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Pefloxacin; Quinolines | 1986 |
CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Quinolines; Regression Analysis | 1987 |
In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Quinolines; Vancomycin | 1987 |